Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (August 2025)
25 slides from Defence Therapeutics Inc Class A's investor presentation, August 2025
Slide 1: Investor Presentation
Investor Presentation Biopharmaceutical Innovations for Future Generations CSE: DTC | FSE: DTC | OTCQB: DTCFF Q3 2025
Slide 2: Forward Looking Statements
Investor Presentation | Defence Theurapeutics Forward Looking Statements DEFENCE THERAPEUTICS This presentation contains “forward-looking information” within the meaning Defence’s short operating history; the possibility that Defence may never receive of applicable securities laws in Canada, includi
Slide 3: Management and Board Members
Investor Presentation | Defence Theurapeutics Management and Board Members Sebastien Plouffe CEO, President, Founder & Director Financial expert and entrepreneur with 30+ years Dr. Philippe Lefrançois experience with publicly listed companies, strong Director management skills Director of Research i
Slide 4: The Highlights
Investor Presentation | Defence Therapeutics THE HIGHLIGHTS Defence Therapeutics ● Publicly traded biotech firm based in Montreal, Canada, with an attractive capital structure and long-term investors. ● Worldwide extensive patent portfolio related he Accum® platform technology, which vastly improves
Slide 5: Problem with Biologics
Investor Presentation | Defence Theurapeutics Problem with Biologics Endosome entrapment limits cellular accumulation of biologics such as ADCs, vaccines (mRNA, DNA, proteins) etc… Cargo (biologics) Cell Endosome Entrapment/degradation Endocytosis Only 1-5% of therapeutics cargo Lysosome spontaneous
Slide 6: Our solution: Accum
Investor Presentation | Defence Theurapeutics Our solution: Accum® Accum®-labelled biologics escape endosomes entrapment and degradation enhancing their cell “Accum®ulation” Biologics+Accum® Cell Accumulation Endosome & Escape Enhanced Therapeutic effect Endocytosis Lysosome 6
Slide 7: Defence Therapeutics: Innovative Platform Accum
Investor Presentation | Defence Theurapeutics Defence Therapeutics: Innovative Platform Accum® Accum® Molecule BILE ACID NLS Highly Versatile Technology Ideal for the development of Easily applicable to mRNA-DNA- Molecules with anti- Augments the anti-tumoral novel cell-based vaccines or protein-bas
Slide 8: Our solution: Accum Innovative Platform
Our solution: Accum® Investor Presentation | Defence Theurapeutics Innovative Platform Accum® Molecule BILE ACID NLS ADC (or any biologics) Accum®-ADC Accum® + Cargo Drug Cargo Drug Cargo Drug Cargo Drug 8 Conjugation of Accum® to existing ADCs (carrying a drug payload) allows the generation of Accu
Slide 9: Pipeline of products in development
Investor Presentation | Defence Theurapeutics Valuable Project Pipeline of products in development Traction With a highly flexible Accum® platform and 100% IP ownership, we have an impactful group of cancer therapies in development. Accum® is well- positioned to achieve data-driven value- Accum® is
Slide 10: The ADC Program
10 CANCER THERAPEUTICS The ADC Program: Accum® significantly improves any ADC 10
Slide 11: Escaping a billion-year-old barrier
Escaping a billion-year-old barrier Antibody-drug conjugate (ADC) Accum confidential 11
Slide 12: Even blockbuster ADC's fall short
Even blockbuster ADC’s fall short Kadcyla Enhertu Padcev $2.2B $3.8B $1.6B Organ damage Lung injury Infections Accum boosts efficacy while reducing toxicity confidential 12
Slide 13: DEFN-101: Accum enhanced Kadcyla
DEFN-101: Accum enhanced Kadcyla ✓ Greater efficacy ✓ Lowered toxicity ✓ Lowered manufacturing cost ✓ Expanded patient population Delivering more benefit to more patients confidential 13
Slide 14: DEFN-101: Kadcyla pairing reduces risk
DEFN-101: Kadcyla pairing reduces risk ✓ Established reagents ✓ Easier clinical path ✓ Existing patient population ✓ Freedom to operate Proven asset, new value confidential 14
Slide 15: Adding value to Kadcyla
Adding value to Kadcyla High HER2 receptor Low HER2 receptor % Cell survival % Cell survival Kadcyla Kadcyla +Accum +Accum Concentration Concentration Accum dramatically increases potency confidential 15
Slide 16: ADC +Accum
ADC +Accum
Slide 17: Validation of Accum with a novel ADC
Validation of Accum with a novel ADC Tumor Volume (mm3) ADC-X (1 mg/kg) + Accum (1 mg/kg) Days Accum revives abandoned ADCs, unlocks new markets confidential 17
Slide 18: Advancing ADC's beyond today's limits
Advancing ADC’s beyond today’s limits Novel IP for endosome escape Works across all ADCs tested Accum Greater drug availability Striking results in xenograft model confidential 18
Slide 19: The Radio-Immuno-Conjugates Programs
19 CANCER THERAPEUTICS The Radio-Immuno-Conjugates Programs: Indications: Solid Tumors 19
Slide 20: Radiopharmaceuticals Programs
Investor Presentation | Defence Theurapeutics Radiopharmaceuticals Programs 1) Accum®/AccuTOX® - Actinium 225 • 100% owned by Defence • Collaboration planned with the Canadian Nuclear Laboratories to perform the studies • Development of targeted radiopharmaceuticals therapy using Accum® & AccuTOX® w
Slide 21: The AccuTOX Program
21 CANCER THERAPEUTICS The AccuTOX® Program: Ready for Phase I in Canada, FDA clearance Study May Proceed in the USA Indication: Melanoma 21
Slide 22: AccuTOX
Investor Presentation | Defence Theurapeutics AccuTOX® Dimers of Accum® have a therapeutic activity by themselves without being conjugated to any biologics + Accum® Accum® AccuTOX® 22 Bikorimana JP, et al., J Transl Med. 2024 Jun 3;22(1):532.
Slide 23: AccuTOX-001 Halts Tumor Development with ICI
Investor Presentation | Defence Theurapeutics AccuTOX-001 Halts Tumor Development When Combined with Immune-Checkpoint Inhibitors (ICI) Synergistic effect against ICI- resistant Tumors 23 Bikorimana JP, et al., J Transl Med. 2024 Jun 3;22(1):532.
Slide 24: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com Laboratories and Offices: 7171 Frederick Banting Montreal, QC, H4S 1Z9
Slide 25: Bibliography Articles
Investor Presentation | Defence Theurapeutics Bibliography Articles 1. Lacasse V et al., Mol Ther Methods Clin Dev. 2020 Sep 1;19:99-119. 2. Paquette M et al., Bioconjug Chem. 2018 Apr 18;29(4):1352- 1363. 3. Beaudoin S et al., Mol Pharm. 2016 Jun 6;13(6):1915-26. 4. El-Kadiry AE et al., Molecules.
Defence Therapeutics — Investor Presentation (August 2025) on 6ix